vs
COMERICA INC（CMA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
COMERICA INC的季度营收约是Revvity的1.1倍（$838.0M vs $772.1M），COMERICA INC净利率更高（21.0% vs 12.7%，领先8.3%），Revvity同比增速更快（5.9% vs 3.3%），过去两年COMERICA INC的营收复合增速更高（108.9% vs 9.0%）
Comerica公司是总部位于美国得克萨斯州达拉斯的金融服务企业，为美国大型金融控股公司之一。旗下Comerica银行为区域性商业银行，在得克萨斯、密歇根、加利福尼亚、佛罗里达、亚利桑那五州共设413家网点，在美国多座城市设有办公场所。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CMA vs RVTY — 直观对比
营收规模更大
CMA
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出2.5%
3.3%
净利率更高
CMA
高出8.3%
12.7%
两年增速更快
CMA
近两年复合增速
9.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $838.0M | $772.1M |
| 净利润 | $176.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 21.0% | 12.7% |
| 营收同比 | 3.3% | 5.9% |
| 净利润同比 | -4.3% | 3.9% |
| 每股收益（稀释后） | $1.35 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMARVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $838.0M | $698.9M | ||
| Q2 25 | $849.0M | $720.3M | ||
| Q1 25 | $829.0M | $664.8M | ||
| Q4 24 | $825.0M | $729.4M | ||
| Q3 24 | $811.0M | $684.0M | ||
| Q2 24 | $824.0M | $691.7M | ||
| Q1 24 | $784.0M | $649.9M |
净利润CMARVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $176.0M | $46.7M | ||
| Q2 25 | $199.0M | $53.9M | ||
| Q1 25 | $172.0M | $42.2M | ||
| Q4 24 | $170.0M | $94.6M | ||
| Q3 24 | $184.0M | $94.4M | ||
| Q2 24 | $206.0M | $55.4M | ||
| Q1 24 | $138.0M | $26.0M |
毛利率CMARVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CMARVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率CMARVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 21.0% | 6.7% | ||
| Q2 25 | 23.4% | 7.5% | ||
| Q1 25 | 20.7% | 6.4% | ||
| Q4 24 | 20.6% | 13.0% | ||
| Q3 24 | 22.7% | 13.8% | ||
| Q2 24 | 25.0% | 8.0% | ||
| Q1 24 | 17.6% | 4.0% |
每股收益（稀释后）CMARVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $1.35 | $0.40 | ||
| Q2 25 | $1.42 | $0.46 | ||
| Q1 25 | $1.25 | $0.35 | ||
| Q4 24 | $1.22 | $0.77 | ||
| Q3 24 | $1.33 | $0.77 | ||
| Q2 24 | $1.49 | $0.45 | ||
| Q1 24 | $0.98 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $5.4B | — |
| 股东权益账面价值 | $7.4B | $7.3B |
| 总资产 | $77.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.73× | — |
8季度趋势，按日历期对齐
现金及短期投资CMARVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务CMARVTY
| Q4 25 | — | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.8B | — | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $6.7B | — | ||
| Q3 24 | $6.8B | — | ||
| Q2 24 | $7.1B | — | ||
| Q1 24 | $7.1B | — |
股东权益CMARVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $7.4B | $7.4B | ||
| Q2 25 | $6.9B | $7.6B | ||
| Q1 25 | $7.1B | $7.6B | ||
| Q4 24 | $6.5B | $7.7B | ||
| Q3 24 | $7.4B | $7.9B | ||
| Q2 24 | $6.2B | $7.9B | ||
| Q1 24 | $6.0B | $7.8B |
总资产CMARVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $77.4B | $12.1B | ||
| Q2 25 | $78.0B | $12.4B | ||
| Q1 25 | $77.6B | $12.4B | ||
| Q4 24 | $79.3B | $12.4B | ||
| Q3 24 | $79.7B | $12.8B | ||
| Q2 24 | $79.6B | $13.4B | ||
| Q1 24 | $79.4B | $13.4B |
负债/权益比CMARVTY
| Q4 25 | — | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.92× | — | ||
| Q2 24 | 1.15× | — | ||
| Q1 24 | 1.18× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-270.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | -1.53× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流CMARVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $-270.0M | $138.5M | ||
| Q2 25 | $476.0M | $134.3M | ||
| Q1 25 | $273.0M | $128.2M | ||
| Q4 24 | $601.0M | $174.2M | ||
| Q3 24 | $1.0B | $147.9M | ||
| Q2 24 | $111.0M | $158.6M | ||
| Q1 24 | $-205.0M | $147.6M |
自由现金流CMARVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率CMARVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度CMARVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率CMARVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | -1.53× | 2.97× | ||
| Q2 25 | 2.39× | 2.49× | ||
| Q1 25 | 1.59× | 3.03× | ||
| Q4 24 | 3.54× | 1.84× | ||
| Q3 24 | 5.70× | 1.57× | ||
| Q2 24 | 0.54× | 2.87× | ||
| Q1 24 | -1.49× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CMA
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
